Citation Impact
Citing Papers
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
Purinergic receptor expression in the apical plasma membrane of rat uterine epithelial cells during implantation
2002
Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade
2008 Standout
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
2009 StandoutNature
Endometriosis
2009
Approaches to improve the diagnosis and management of infertility
2009
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study
2008
Rethinking mechanisms, diagnosis and management of endometriosis
2019 Standout
The physiology and clinical utility of anti-Müllerian hormone in women
2014 Standout
Constitutive interaction of the P2Y2 receptor with the hematopoietic cell-specific G protein Gα16 and evidence for receptor oligomers
2004
Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers
2016
Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles
2007
The Prevention of Ovarian Hyperstimulation Syndrome
2014
Cellular Distribution and Functions of P2 Receptor Subtypes in Different Systems
2004
Dimerization of G protein-coupled purinergic receptors: increasing the diversity of purinergic receptor signal responses and receptor functions
2010
Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
2010 StandoutNature
Endometriosis: current and future medical therapies
2007
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells
2003
P2 receptors and cancer
2006
Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century
2015 Standout
Endometriosis: pathogenesis and treatment
2013 Standout
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria
2011 Standout
P2Y2 Nucleotide Receptors Enhance α-Secretase-dependent Amyloid Precursor Protein Processing
2005
Signaling by extracellular nucleotides in anterior pituitary cells
2001
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
2017 Standout
Molecular Physiology of P2X Receptors
2002 Standout
Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
2009
Treatment of central precocious puberty
2006
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
2006
Current and emerging treatment options for endometriosis
2018
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
2017 Standout
Receptors for Purines and Pyrimidines
2012 Standout
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Physiology of Microglia
2011 Standout
Works of A. Schultze-Mosgau being referenced
New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists
2005
Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study
2007
Expression and Responsiveness of P2Y2Receptors in Human Endometrial Cancer Cell Lines
1999
Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol
2005
Cetrorelix in the treatment of female infertility and endometriosis
2006
Characterization of calcium-mobilizing, purinergic P2Y2 receptors in human ovarian cancer cells
2000
Five years' clinical use of GnRH antagonists: evaluation of safety and allergic potential
2005
A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists
2005